annovisbio.com valid

Annovis Bio, Inc. (NYSE: ANVS)

Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targetin

For agents: Annovis Bio (NYSE: ANVS) clinical-stage biotech developing buntanetap for Alzheimer's and Parkinson's; covers pipeline, Phase 3 trials and patents.

buntanetapalzheimers diseaseparkinsons diseaseclinical trialsneurodegeneration

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-21T11:40:55.223Z. Cached copy · Source on annovisbio.com

# Annovis Bio, Inc. (NYSE: ANVS)

> Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action.

Buntanetap is an investigational drug candidate that is still being studied in clinical trials.

## Company
- [About Us](https://www.annovisbio.com/about-us): Mission, management team, and board of directors
- [Our Science](https://www.annovisbio.com/our-science): How buntanetap works
- [Pipeline](https://www.annovisbio.com/pipeline): Buntanetap programs in Alzheimer's and Parkinson's diseases, with clinical trial results
- [Intellectual Property](https://www.annovisbio.com/intellectual-property): Patents covering buntanetap

## Clinical trials
- [Pivotal Phase 3 Alzheimer's Study](https://www.annovisbio.com/alzheimers-disease): Double-blind study of buntanetap in early Alzheimer's disease (NCT06709014), fully enrolled with 862 patients
- [Alzheimer's Open-Label Extension](https://www.annovisbio.com/alzheimers-open-label-extenstion): Continued buntanetap access for Phase 3 participants
- [Parkinson's Open-Label Study](https://www.annovisbio.com/parkinsons-disease): Long-term study of buntanetap in Parkinson's disease (NCT07284784)
- [Patient Portal](https://www.annovisbio.com/patient-portal): Trial eligibility and how to participate
- [Expanded Access Policy](https://www.annovisbio.com/expanded-access-policy)

## News and investors
- [Press Releases](https://www.annovisbio.com/press-release): All company announcements
- [Investor Relations](https://www.annovisbio.com/investors-relations): Investor overview, presentations, and events
- [SEC Filings](https://www.annovisbio.com/sec-fillings)
- [Quarterly Earnings](https://www.annovisbio.com/quarterly-earnings)
- [Investor FAQ](https://www.annovisbio.com/faq)
- [Publications](https://www.annovisbio.com/publications): Peer-reviewed research on buntanetap
- [Posters & Presentations](https://www.annovisbio.com/posters-presentations): Scientific conference materials

## Contact
- Investor relations: ir@annovisbio.com
- Clinical trials: clinicaltrials@annovisbio.com
- General: info@annovisbio.com, +1 (484) 875-3192, 101 Lindenwood Drive, Suite 225, Malvern, PA 19355

Related sites

Other listed sites in Healthcare. See the whole category →

Machine-readable: GET /v1/resolve?q=annovisbio.com · GET /v1/domain/annovisbio.com · this page as Accept: application/json or text/markdown · MCP lookup_domain

Automatically discovered from public files. Inclusion does not imply endorsement or publisher participation.

Claim my listing on Agent Web Map for annovisbio.com:
1. POST https://agentwebmap.com/v1/sites/annovisbio.com/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://annovisbio.com/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/annovisbio.com/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/annovisbio.com).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory.